A Randomized Trial of Adjuvant Chemotherapy With Standard Regimens, Cyclophosphamide, Methotrexate and Fluorouracil - (CMF) or Doxorubicin and Cyclophosphamide - (AC), Versus Capecitabine in Women 65 Years and Older With Node Positive or Node-Negative Breast Cancer.
Latest Information Update: 20 May 2022
At a glance
- Drugs Capecitabine (Primary) ; Cyclophosphamide; Cyclophosphamide; Doxorubicin; Fluorouracil; Methotrexate
- Indications Adenocarcinoma; Early breast cancer
- Focus Therapeutic Use
- 13 Apr 2022 Results pooled analysis of NCT00005970, NCT00024102, evaluating Role of age, BMI, and tumor subtype in racial/ethnic disparities in breast cancer survival, presented at the 113th Annual Meeting of the American Association for Cancer Research
- 14 Dec 2019 Results (N= 15,457), a metanalysis of prospective randomized trials assessing efficacy of Capecitabine as a part of neo adjuvant or adjuvant therapy in patients with early breast cancer, presented at the 42nd Annual San Antonio Breast Cancer Symposium
- 24 Jul 2019 Results (n=633) published in the Journal of Clinical Oncology.